Los Angeles Capital Management LLC Halozyme Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

$24.2 Billion
Q4 2024

A detailed history of Los Angeles Capital Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 92,475 shares of HALO stock, worth $5.36 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

92,475

Previous 110,630 16.41%

Holding current value

$5.36 Million

Previous $6.33 Million 30.15%

% of portfolio

0.02%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	SELL	$42.57 - $61.09 $772,858 - $1.11 Million	-18,155 Reduced 16.41%	92,475 $4.42 Million
Q3 2024 Nov 04, 2024	SELL	$51.3 - $64.42 $289,434 - $363,457	-5,642 Reduced 4.85%	110,630 $6.33 Million
Q2 2024 Aug 05, 2024	SELL	$37.81 - $52.4 $178,765 - $247,747	-4,728 Reduced 3.91%	116,272 $6.09 Million
Q1 2024 Apr 05, 2024	BUY	$33.68 - $41.95 $596,674 - $743,186	17,716 Added 17.15%	121,000 $4.92 Million
Q4 2023 Feb 06, 2024	BUY	$33.32 - $42.1 $66,206 - $83,652	1,987 Added 1.96%	103,284 $3.82 Million
Q3 2023 Nov 06, 2023	BUY	$36.46 - $44.03 $358,365 - $432,770	9,829 Added 10.75%	101,297 $3.87 Million
Q2 2023 Aug 03, 2023	BUY	$30.28 - $38.74 $556,788 - $712,351	18,388 Added 25.16%	91,468 $3.3 Million
Q1 2023 May 04, 2023	SELL	$32.86 - $55.7 $2.61 Million - $4.42 Million	-79,308 Reduced 52.04%	73,080 $2.79 Million
Q4 2022 Feb 06, 2023	SELL	$40.06 - $59.44 $1.15 Million - $1.71 Million	-28,765 Reduced 15.88%	152,388 $8.67 Million
Q3 2022 Nov 02, 2022	SELL	$38.53 - $51.78 $557,143 - $748,738	-14,460 Reduced 7.39%	181,153 $7.16 Million
Q2 2022 Aug 05, 2022	BUY	$37.35 - $48.3 $65,138 - $84,235	1,744 Added 0.9%	195,613 $8.61 Million
Q4 2021 Feb 03, 2022	BUY	$31.82 - $40.75 $3.97 Million - $5.09 Million	124,880 Added 181.01%	193,869 $7.8 Million
Q3 2021 Nov 08, 2021	BUY	$38.47 - $46.42 $560,315 - $676,107	14,565 Added 26.76%	68,989 $2.81 Million
Q2 2021 Aug 05, 2021	SELL	$38.84 - $51.31 $583,415 - $770,727	-15,021 Reduced 21.63%	54,424 $2.47 Million
Q1 2021 May 05, 2021	SELL	$39.51 - $51.45 $1.75 Million - $2.27 Million	-44,216 Reduced 38.9%	69,445 $2.9 Million
Q4 2020 Feb 04, 2021	BUY	$25.81 - $43.62 $45,941 - $77,643	1,780 Added 1.59%	113,661 $4.85 Million
Q3 2020 Nov 02, 2020	SELL	$25.74 - $29.63 $813,281 - $936,189	-31,596 Reduced 22.02%	111,881 $2.94 Million
Q2 2020 Aug 05, 2020	BUY	$16.25 - $26.81 $23,822 - $39,303	1,466 Added 1.03%	143,477 $3.85 Million
Q1 2020 May 04, 2020	BUY	$13.9 - $21.83 $920,777 - $1.45 Million	66,243 Added 87.43%	142,011 $2.56 Million
Q4 2019 Feb 07, 2020	SELL	$14.93 - $19.53 $1.12 Million - $1.47 Million	-75,281 Reduced 49.84%	75,768 $1.34 Million
Q3 2019 Nov 07, 2019	SELL	$15.2 - $17.69 $900,828 - $1.05 Million	-59,265 Reduced 28.18%	151,049 $2.34 Million
Q2 2019 Jul 29, 2019	SELL	$14.75 - $17.26 $914,868 - $1.07 Million	-62,025 Reduced 22.77%	210,314 $3.61 Million
Q1 2019 Apr 25, 2019	SELL	$13.94 - $17.58 $42,517 - $53,618	-3,050 Reduced 1.11%	272,339 $4.39 Million
Q4 2018 Feb 11, 2019	BUY	$13.33 - $18.66 $538,998 - $754,517	40,435 Added 17.21%	275,389 $4.03 Million
Q3 2018 Nov 05, 2018	BUY	$16.68 - $18.41 $2.64 Million - $2.91 Million	158,240 Added 206.27%	234,954 $4.27 Million
Q2 2018 Jul 31, 2018	SELL	$16.87 - $20.3 $74,902 - $90,132	-4,440 Reduced 5.47%	76,714 $1.29 Million
Q1 2018 Apr 27, 2018	BUY	$17.06 - $21.2 $470,344 - $584,484	27,570 Added 51.45%	81,154 $1.59 Million
Q4 2017 Feb 05, 2018	BUY	$16.75 - $20.8 $678,944 - $843,107	40,534 Added 310.61%	53,584 $1.09 Million
Q3 2017 Nov 06, 2017	BUY	$11.76 - $17.4 $153,468 - $227,069	13,050	13,050 $227,000

Others Institutions Holding HALO

# of Institutions

548

Shares Held

124M

Call Options Held

668K

Put Options Held

259K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.07B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Account

Los Angeles Capital Management LLC Halozyme Therapeutics, Inc. Transaction History